Empagliflozin in type 1 diabetes

Código QR

Empagliflozin in type 1 diabetes

Chantal Mathieu, Laura Van Den Mooter, Bert EeckhoutEndocrinology, UZ Gasthuisberg, Leuven 3000, BelgiumCorrespondence: Chantal MathieuEndocrinology, UZ Gasthuisberg, Herestraat 49, Leuven 3000, BelgiumEmail chantal.mathieu@uzleuven.beAbstract: There is a clear unmet need in people living with type...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mathieu C, Van Den Mooter L, Eeckhout B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	type 1 diabetes SGLT2 inhibitor empagliflozin EASE trials Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/98d3c9d7fe344aa798dd92c4723adf3c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019)

Empagliflozin: a new strategy for nephroprotection in diabetes
por: Anton Ivanovich Korbut, et al.
Publicado: (2017)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Canagliflozin review – safety and efficacy profile in patients with T2DM
por: Jakher H, et al.
Publicado: (2019)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
por: Seko Y, et al.
Publicado: (2018)

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Empagliflozin Regulates the AdipoR1/p-AMPK/p-ACC Pathway to Alleviate Lipid Deposition in Diabetic Nephropathy
por: Zhang Z, et al.
Publicado: (2021)

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population
por: Shen L, et al.
Publicado: (2021)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker CM, et al.
Publicado: (2016)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
por: Liu S, et al.
Publicado: (2019)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu H, et al.
Publicado: (2017)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
por: Ndibalema AR, et al.
Publicado: (2020)

Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage and Dietary Administration by Focusing on Fatty Acid Metabolism
por: Kawarasaki S, et al.
Publicado: (2020)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir KM, et al.
Publicado: (2016)

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
por: Men P, et al.
Publicado: (2020)

Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
por: Gillani Syed Wasif, et al.
Publicado: (2021)

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice
por: Chiang-Chi Huang, et al.
Publicado: (2021)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh S, et al.
Publicado: (2016)

In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia
por: Martina Hüttl, et al.
Publicado: (2021)

Saxagliptin for type 2 diabetes
por: Chacra
Publicado: (2010)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
por: A. V. Simanenkova, et al.
Publicado: (2021)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

Overview of Clinical Trials on Type 2 Diabetes Mellitus: A Comprehensive Analysis of the ClinicalTrials.gov Database
por: Long J, et al.
Publicado: (2021)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
por: Levin PA, et al.
Publicado: (2017)

Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice
por: Jiang YK, et al.
Publicado: (2019)

Urban-Rural Differences in the Trends of Type 1 and Type 2 Diabetes Among Adults Who Received Medical Treatment from Public Hospitals in Resource-Poor Community Tigray, Ethiopia
por: Gebremedhin G, et al.
Publicado: (2020)

Empagliflozin as a new management strategy on outcomes in patients with type 2 diabetes mellitus
por: Vladimir V. Salukhov, et al.
Publicado: (2016)

Heart failure outcomes in patients with type 2 diabetes mellitus: findings from the cardiovascular outcome trials of antidiabetes agents
por: Stefan D. Anker
Publicado: (2019)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Depression in people with type 2 diabetes: current perspectives
por: Darwish L, et al.
Publicado: (2018)

Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension
por: Silvie Hojná, et al.
Publicado: (2021)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)

Higher Serum Asprosin Level is Associated with Urinary Albumin Excretion and Renal Function in Type 2 Diabetes
por: Deng X, et al.
Publicado: (2020)

The Effects of Type 2 Diabetes and Postoperative Pneumonia on the Mortality in Inpatients with Surgery
por: Ma C, et al.
Publicado: (2019)

Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus
por: Tafere GG, et al.
Publicado: (2020)

Hepatic Steatosis Index Is Associated with Type 1 Diabetes Complications
por: Tripolino C, et al.
Publicado: (2019)